Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00989 ...
Drug Name Rivastigmine
Molecular Weight 250.3367
Molecular Formula C14H22N2O2
CAS Number 123441-03-2
SMILES CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
External Links
DRUGBANK DB00989
PubChem Compound 77991
PDR 423
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 2.3 - 2.3 - DRUGBANK

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 72.0 % 72(22-119) % The Pharmacological Basis of Therapeutics
C Max 26.0 ng/ml 26±10 ng/ml Capsule, PO, Oral; The Pharmacological Basis of Therapeutics
T Max 1.2 h 1.2±1.0 h Capsule, PO, Oral; The Pharmacological Basis of Therapeutics
Clearance 2.5 L/h 2.1-2.8 L/h Renal clearance; DRUGBANK
Clearance 0.78 L/h/kg 13±4 ml/min/kg intravenous injection, IV; The Pharmacological Basis of Therapeutics
Clearance 0.72 L/h/kg 12 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 2.3 L/kg 1.8-2.7 L/kg DRUGBANK
Volume of Distribution 0.15 L/kg 1.5±0.6 L/kg intravenous injection, IV; The Pharmacological Basis of Therapeutics
Volume of Distribution 1.3 L/kg 1.3 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 1.5 h 1.5 h DRUGBANK
Half-life 1.4 h 1.4±0.4 h intravenous injection, IV; RD, renal impairment, Renal disease，including uremia ↑ ; The Pharmacological Basis of Therapeutics
Half-life 10.0 h ~10 h The Pharmacological Basis of Therapeutics
Half-life 1.4 h 1.4 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Eliminate Route 1.0 % <1 % Faeces excretion; DRUGBANK
Eliminate Route 0 % ~0 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 40.0 % 40 % DRUGBANK
Protein Binding 40.0 % 40 % The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for adults 12.0 mg/day 12 mg/day Capsule, PO, Oral Exelon Capsules and Oral Solution rivastigmine tartrate PDR
Max dose for adults 13.3 mg/day 13.3 mg/day Transdermal preparations Exelon Capsules and Oral Solution rivastigmine tartrate PDR
Max dose for geriatric 12.0 mg/day 12 mg/day Capsule, PO, Oral Exelon Capsules and Oral Solution rivastigmine tartrate PDR
Max dose for geriatric 13.3 mg/day 13.3 mg/day Transdermal preparations Exelon Capsules and Oral Solution rivastigmine tartrate PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1